National Resilience, months after launching with $800M, snags Sanofi biomanufacturing plant

Resilience launched in November with plans to shore up manufacturing of cutting-edge medicines like cell and gene therapies, viral vectors, proteins and vaccines. (Business Wire)

A few short months after its launch, biomanufacturing and technology company National Resilience, led by former Novavax chief Rahul Singhvi, is moving forward with its ambitious expansion plans.

Resilience has picked up two commercial facilities in Canada and the U.S., lifting its North American footprint to more than 750,000 square feet. The company set out late last year to establish a network of biopharma manufacturing sites with backing from leading venture firms and an impressive roster of executives and board members.

The expansion comes just months after Resilience's November 2020 launch, when the company unveiled its mission to build the "world's most advanced biopharmaceutical manufacturing ecosystem." The company set out with more than $800 million in capital, laying plans to invest in new technologies for the production of cutting-edge meds like cell and gene therapies, viral vectors, vaccines and proteins. 

This month, National Resilience acquired a former Genzyme manufacturing plant from Sanofi in Boston, where it’s agreed to keep making an unnamed, marketed product. The company says it will build out the 310,000-square-foot site, located on land owned by Harvard University, for multi-modality manufacturing. It also plans new quality labs there.

RELATED: Sanofi Genzyme trims 130 workers at Boston plant after unit reports strong global Q4 growth

The Sanofi site houses multiple 2,000-liter bioreactors and downstream processing trains. Resilience says it's plotting upgrades to turn out new therapies at the site, which is now the largest plant in its biologics and advanced therapeutics manufacturing network.

Resilience has made job offers to the 250 staffers currently employed at the Boston site, with plans to make additional hires in the future, The Harvard Gazette reports

Moving North, the company also acquired a 136,000-square-foot commercial plant in Mississauga, Canada, where it will also look to retain existing staff, make new hires and invest in facility upgrades. The facility is equipped to handle upstream, downstream and aseptic fill-finish work, Resilience said.

"COVID-19 has exposed critical vulnerabilities in medical supply chains, and today's manufacturing can't keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale," Robert Nelsen, founder and chairman of Resilience, said in a release at the time of the company's launch. "We are committed to tackling these huge problems with a whole new business model," he added.

The company is setting up a "sustainable network of high-tech, end-to-end manufacturing solutions" to make current and future drugs "quickly, safely, and at scale," Resilience said in a release.

RELATED: MIT spinout Continuus Pharmaceuticals nets $69M to onshore production of critical meds

At the time of launch, National Resilience had raised more than $800 million. The funding round was led by ARCH Venture Partners and 8VC, with GV and NEA chipping in alongside investors that included large U.S. drugmakers and foundations. 

The company is led by former Novavax CEO and COO of Takeda vaccines Singhvi. Celgene and Sarepta Therapeutics vet Sandy Mahatme serves as president, chief operating officer and chief financial officer, and former Juno Therapeutics and Roche/Genentech EVP Patrick Yang is Resilience's vice chairman. The company also counts former FDA commissioner Scott Gottlieb among its founding board of directors.